NIDA-CTO-0008

Division
DTMC
HEAL Study
No
Investigator(s)
Richard Rawson, Ph.D.
Title
Phase 2, Double-Blind Placebo-Controlled Trial Of Bupropion for the Treatment of Methamphetamine Dependence
Short Description
The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence.
Release Date
May 07, 2018
Description

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Keywords
bupropion
methamphetamine
phase 2b
stimulant
Assessments
Addiction Severity Index Lite
Brief Substance Craving Scale
Clinical Global Impression Scales
Hamilton – Depression Rating Scale
HIV Risk-Taking Behaviour Scale
Methamphetamine Withdrawal Questionnaire
Stroop Color Word Task
Substance Use Report
Trail Making Test
Urine Methamphetamine Level
Wechsler Adult Intelligence Scale Digit Symbol subtest
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
CTO-0008 Data
Study Links
Primary Manuscript
https://www.nature.com/articles/1301481
ClinicalTrials.gov Link
https://clinicaltrials.gov/ct2/show/NCT00069251
Study Documents
Protocol
CTO0008-Protocol.pdf
Dictionary
CTO0008_DD.xlsx
Case Report Form(s)
CTO0008-CRF.pdf
Deidentification Notes
CTO0008-DeidentificationNotes.pdf
Nulled Values
CTO0008-nulled-values.csv
All Documents
CTO0008-AllDocuments.zip